StreetInsider.com News Articles

Form 4 VERACYTE, INC. For: Sep 14 Filed by: Holstein Jens

Wed, 16 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260916/27070339.html

Needham Reiterates Buy Rating on Veracyte, Inc (VCYT)

Tue, 15 Sep 2026 05:22:00 -0400

Needham analyst Mike Matson reiterated a Buy rating and $69.00 price target on Veracyte, Inc (NASDAQ: VCYT).

The analyst comments "Yesterday, after the close, VCYT announced the acquisition of Convergent Genomics for $150M of upfront cash plus up to $30M in additional milestone payments. Convergent Genomics has developed a tumor-naive minimal residual disease (MRD) assay called UroAmp for non-muscle-invasive bladder cancer (NMIBC) patients. UroAmp is a non-invasive, genomic assay that analyzes 60 urothelial cancer-related genes in a patient's urine, as well as broader changes across a patient's genome. The test has been validated with the RUMBLE study (n=57) which showed

Form 144 VERACYTE, INC. Filed by: Holstein Jens

Mon, 14 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260914/27059155.html

Form 8-K VERACYTE, INC. For: Sep 10

Mon, 14 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260914/27058458.html

Veracyte acquires Convergent Genomics for up to $180M

Mon, 14 Sep 2026 16:05:17 -0400

Veracyte, Inc. (NASDAQ: VCYT) announced the acquisition of Convergent Genomics, adding the UroAmp urinary tumor DNA (utDNA) testing platform to its diagnostics portfolio, according to a company press release dated Sept. 14, 2026.

The deal includes $150 million in upfront cash and up to $30 million in additional cash tied to reimbursement-related milestones. Veracyte said the acquisition's ongoing operating expenses were already reflected in its previously provided 2026 adjusted EBITDA guidance, which the company is not updating.

UroAmp analyzes tumor-derived genomic information from urine samples and has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Mon, 14 Sep 2026 16:05:00 -0400

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.

In the U.S., there are approximately 85,000 patients diagnosed with bladder

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Mon, 14 Sep 2026 16:05:00 -0400

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

In the U.S., there are approximately 85,000 patients diagnosed with bladder

Form 4 VERACYTE, INC. For: Sep 02 Filed by: Chambers Rebecca